You’re using a public version of DrugPatentWatch with 5 free searches available | Register to unlock more free searches. CREATE FREE ACCOUNT

Last Updated: March 5, 2024

Investigational Drug Information for Imeglimin


✉ Email this page to a colleague

« Back to Dashboard


What is the drug development status for Imeglimin?

Imeglimin is an investigational drug.

There have been 7 clinical trials for Imeglimin. The most recent clinical trial was a Phase 2 trial, which was initiated on June 1st 2022.

The most common disease conditions in clinical trials are Diabetes Mellitus, Type 2, Diabetes Mellitus, and Liver Diseases. The leading clinical trial sponsors are Poxel SA, Sumitomo Pharma Co., Ltd., and National Center for Global Health and Medicine, Japan.

There are sixteen US patents protecting this investigational drug and two hundred and sixty-two international patents.

Recent Clinical Trials for Imeglimin
TitleSponsorPhase
Durable Effect of Imeglimin on the Glycemic Control in Patients With Type 2 Diabetes MellitusSumitomo Pharma Co., Ltd.Phase 4
Durable Effect of Imeglimin on the Glycemic Control in Patients With Type 2 Diabetes MellitusNational Center for Global Health and Medicine, JapanPhase 4
Pharmacokinetics of Imeglimin in Hepatic Impaired SubjectsPoxel SAPhase 1

See all Imeglimin clinical trials

Clinical Trial Summary for Imeglimin

Top disease conditions for Imeglimin
Top clinical trial sponsors for Imeglimin

See all Imeglimin clinical trials

US Patents for Imeglimin

Drugname Patent Number Patent Title Patent Assignee Estimated Expiration
Imeglimin ⤷  Try a Trial Biguanide compositions and methods of treating metabolic disorders ELCELYX THERAPEUTICS, INC. (San Diego, CA) ⤷  Try a Trial
Imeglimin ⤷  Try a Trial Controlled release dosage form TRIASTEK, INC. (Nanjing, CN) ⤷  Try a Trial
Imeglimin ⤷  Try a Trial Biguanide compositions and methods of treating metabolic disorders Anji Pharma (US) LLC (Boxford, MA) ⤷  Try a Trial
Imeglimin ⤷  Try a Trial Separation of triazine derivatives enantiomers using tartaric acid Poxel (Lyons, FR) ⤷  Try a Trial
Imeglimin ⤷  Try a Trial Biguanide compositions and methods of treating metabolic disorders Elcelyx Therapeutics, Inc (San Diego, CA) ⤷  Try a Trial
Imeglimin ⤷  Try a Trial Process of isolating enantiomer components from enantiomer mixtures by particle-size-controlled crystallization Poxel (Lyons, FR) ⤷  Try a Trial
>Drugname >Patent Number >Patent Title >Patent Assignee >Estimated Expiration

International Patents for Imeglimin

Drugname Country Document Number Estimated Expiration Related US Patent
Imeglimin Argentina AR091089 2031-01-07 ⤷  Try a Trial
Imeglimin Argentina AR091739 2031-01-07 ⤷  Try a Trial
Imeglimin Australia AU2011317140 2030-10-19 ⤷  Try a Trial
Imeglimin Australia AU2011317143 2030-10-19 ⤷  Try a Trial
Imeglimin Australia AU2012204162 2030-10-19 ⤷  Try a Trial
Imeglimin Australia AU2012363873 2030-10-19 ⤷  Try a Trial
>Drugname >Country >Document Number >Estimated Expiration >Related US Patent

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.